New Zealand surrogacy: medical and donor requirements explained
How to classify a proposed treatment
In New Zealand, the question is not simply whether a surrogate, egg donor or sperm donor is medically suitable. First identify the procedure, the people supplying gametes or embryos, the clinic's proposed treatment and whether case-specific approval is needed. The Human Assisted Reproductive Technology Act 2004 (HART Act), the Human Assisted Reproductive Technology Order 2005 and ACART's 2020 donation and surrogacy guidelines address different legal layers. Clinical screening and a clinic's acceptance policy are another layer. A positive medical assessment alone is neither an ECART approval nor an assurance of legal parenthood.
The HART Order identifies established procedures, including ordinary IVF, gamete collection, artificial insemination and relevant storage procedures; ordinarily these do not need individual ECART approval merely because they are performed. But the same treatment plan may include clinic-assisted surrogacy, embryo donation, use of eggs and sperm from two donors or particular intrafamily donations. Those features can trigger ethics review under the Act, Order and ACART guidelines. ECART's official procedure list specifically places clinic-assisted surrogacy in its review column. Ask the clinic to classify the whole plan, not just the laboratory technique. An IVF technique being established does not exempt an IVF-based clinic-assisted surrogacy arrangement from ECART review: ECART classifies the surrogacy arrangement, not simply the laboratory step.
What ECART checks
For a proposed clinic-assisted surrogacy, the clinic submits an application to the Ethics Committee on Assisted Reproductive Technology (ECART) before proceeding. ACART guidelines require ECART to assess consent, freedom from undue influence, the interests of any child, the parties' relationships and whether the procedure is the best or only opportunity for the intending parents rather than social or financial convenience. These are assessment criteria, not a blanket rule that a single diagnosis, citizenship category or genetic connection automatically decides every case. A medical letter should explain the actual clinical reasons for the proposed pathway.
Surrogacy-specific review focuses on whether risks to the gestational carrier, intending parents, donors if relevant, and the future child are justified. The 2020 guidelines expressly include pregnancy and birth risks, effects on the surrogate's future fertility, possible changes of mind, a potential disagreement over care and the impact of the parties' residency and plans on a child born in New Zealand. Counselling must address ongoing contact, individual and joint discussions, and support before and after pregnancy. A willing carrier is essential but willingness by itself does not answer those risks.
The 2020 ACART guidelines require parties in an ECART application involving surrogacy to receive independent legal advice; all parties must receive independent medical advice, and reports must show understanding of the consequences. Counselling must be culturally appropriate, consider whānau or extended family and existing children where relevant, and cover genetic origins, future contact, storage and disposal, disability or genetic conditions, and possible pregnancy termination. Separate advice and documented consent protect autonomy: intended parents cannot treat a surrogate's agreement as advance permission to control medical decisions during pregnancy.
Gestational and donor consent
The gamete route materially changes the consent evidence. When an embryo is created from donated eggs and/or donated sperm, ECART must be satisfied that those gamete donors consented to the specific proposed use, either when donating or later, and had implications counselling before agreeing. Under the guidelines, a gamete donor who consented before embryo creation may vary or withdraw that consent only until the embryo is created. That timing rule must not be confused with the separate rules for a donated embryo. Recheck old donor forms where proposed use has changed since the 2020 guidelines.
Donating an already-created embryo is a distinct route. The original intending parent or parents must consent to the contemplated donation, at the time of donation or when the later use is proposed; under the guidelines they may vary or withdraw before embryo transfer. For re-donation or on-donation, additional consent, full-sibling and family-history conditions apply. The 2020 guidance also requires joint counselling, agreement about unused embryos and Police vetting of embryo recipients. Do not assume that consent for ordinary IVF, storage, embryo donation and transfer to a surrogate are legally interchangeable. For a first embryo donation, the embryos must have been created for the original intending parents’ own fertility treatment and be surplus because they have completed their family or no longer intend to have children. Every embryo donation, re-donation and on-donation requires an ECART application. On-donation by recipients is permitted under the guidelines only where the original intending parents contributed no gametes and had no full-genetic-sibling offspring, but the recipients did have such offspring.
Donor combinations and genetic origins
There is no sound shortcut such as “a surrogate programme must always use the intended mother's eggs” or “two donated gametes are necessarily unlawful.” The 2020 ACART guidelines expressly address embryos made using donated eggs together with donated sperm, subject to their conditions and any applicable ECART review. An embryo donated after creation is another category. Record whether each gamete is from an intending parent or a donor, whether the carrier contributes a gamete, whether an embryo already exists, and who has previously used embryos from the same donors. Each change can alter the approval and consent route.
Donor information is not merely a matter of private preference. Part 3 of the HART Act sets rules for provider records and access to identifying information about donors and donor-conceived offspring, including the HART register. New Zealand government guidance states that donors supply identity details and that identifying information may be available to offspring under statutory conditions. Counselling should address disclosure to the child and future contact. Before importing or using gametes or embryos obtained elsewhere, ask the clinic how it will meet New Zealand consent, provenance and recordkeeping duties; do not assume a foreign anonymous-donor form suffices.
Medical screening and clinic policies
Donor recruitment pages are not universal legislation. The New Zealand government describes usual sperm-donor ages of 20–45 and egg-donor ages of 20–37, with blood tests and other assessments; it separately notes that most clinics limit sperm use to five families. These are publicly described ordinary clinic practices, not proof of a statutory age limit or absolute rule for every programme. The legally important distinction is between a source that expressly imposes a requirement and a provider's medical risk threshold. Ask for the written clinical policy and any reasoned exception procedure rather than relying on an advertisement.
Clinical assessment may involve an obstetric evaluation of pregnancy risks for the proposed surrogate, reproductive history, infectious-disease tests, relevant genetic and family history, and a review of the donors' suitability. The exact screening panel, acceptable body-mass index, smoking policy, previous-pregnancy criteria, age limits and laboratory protocols must be confirmed with the treating provider; the cited legal materials do not establish one universal numeric threshold for all those factors. Fertility providers also operate within New Zealand's health-service quality regime, including NZS 8134:2021 Ngā Paerewa, which replaced the old fertility services standard from 28 February 2022.
Family donors and limits
Family donation requires special classification. ACART guidelines forbid approval where a resulting child would be conceived from gametes donated by specified close genetically related pairs, including siblings and parent–child pairs. At the same time, some narrower egg donations from the recipient woman’s sister or cousin, or sperm donations from her spouse’s or partner’s brother or cousin, are described as not requiring separate ethics approval if the stated age and relationship conditions are met. These exceptions do not remove the need for clinical screening or override the surrogacy review. Family relationships, age 20 conditions in listed examples and potential undue influence should be documented rather than assumed.
A different numerical rule governs full genetic siblings under the 2020 ECART guidelines: no more than two families may have offspring who are full genetic siblings through the relevant donation procedure, while a donor may separately donate eggs or sperm in another arrangement. This is not the same as the government website's statement about clinics commonly using sperm for at most five families. Embryo re-donation adds particular original-parent and recipient consent tests. If prior donations exist, seek a written record of the donor history, existing full-sibling families and the proposed embryo's genetic relationships before asking ECART to assess the plan.
Application dossier and decisions
An ECART submission should be prepared through the fertility clinic using the official application format. In practice, first request a clinical plan identifying all participants, gamete/embryo origins and reasons for surrogacy; then assemble medical opinions and screening results, individual and joint counselling reports, all relevant donor and surrogate consents, independent legal advice reports, and a plan for contact, care and child welfare. Identify residence plans and any pre-existing embryo storage or use agreements. Ask the clinic which documents are mandatory on the current form and whether additional consent is necessary for any amended treatment.
ECART can approve, approve with conditions, defer or decline an application according to its published process. Approval does not oblige a clinic to offer a medically unsuitable treatment, and clinic acceptance cannot replace ethics approval when required. If the application is deferred or refused, request the precise grounds and distinguish missing information, remediable counselling or consent gaps, medical concerns and a substantive legal bar. Correct the dossier and ask the clinic about reconsideration or a fresh application as appropriate; do not claim there is an automatic entitlement to appeal or to treatment without a checked legal basis.
Safe next steps
The HART Act separately restricts commercial supply of gametes and embryos and commercial surrogacy arrangements; these prohibitions should not be disguised as an informal donation arrangement. New Zealand surrogacy agreements are not enforceable as a promise to carry or hand over a child. The scope here is medical and donor conditions, not a complete analysis of expenses or later parentage, adoption, birth registration, immigration or nationality. Nevertheless, decisions about pregnancy and donor choice can affect those later steps, especially where parties live abroad. Obtain distinct New Zealand legal advice on family-status consequences before transfer. Section 14(4) of the HART Act excepts defined payments to providers for reasonable and necessary listed services, including gamete or embryo handling, counselling and IVF, and payment for independent legal advice to the surrogate; it is not general permission to pay a surrogate or intermediary. As of 25 October 2026, the Improving Arrangements for Surrogacy Bill was still awaiting its second reading. Its proposed changes to legal parentage and surrogacy arrangements must not be treated as current law.
Before paying for treatment or creating embryos, ask the clinic for a written five-part answer: which elements are established procedures and which need ECART approval; what documented medical reason and surrogate risk review supports the plan; whose gametes/embryos are used and what consent remains effective; which screening limits are law, accreditation standards or clinic policy; and which reports and signatures the clinic will submit. Seek an explanation of any refusal in writing. For cross-border participants, coordinate separately with counsel in each affected country. This is a decision framework, not an individual approval or medical clearance.
Official sources and primary materials
- S01: HART Act 2004, current legislation (10 July 2026 version)
- S02: HART Order 2005 (established procedures)
- S03: ACART 2020 Donation and Surrogacy Guidelines
- S04: ECART: about us and procedure classification
- S05: ECART: ethics review process
- S06: ECART: current application forms
- S07: New Zealand Government: Donate sperm or eggs
- S08: Standards NZ: health care services standards
- S09: ACART: donation and surrogacy guidance page
- S10: NZ Ministry of Justice — current surrogacy parentage and pending reform (updated 20 October 2026)
- S11: NZ Parliament — Improving Arrangements for Surrogacy Bill, legislative stage (25 October 2026)
